ATAGI recommendations 

Use of Shingrix versus Zostavax in immunocompetent adults aged ≥50 years

Use of Shingrix in immunocompromised adults aged ≥18 years

Use of Shingrix in immunocompetent adults aged ≥50 years

 

GRADE assessment of recombinant herpes zoster vaccine (Shingrix)

Immunocompetent older adults compared to placebo

Immunocompetent older adults compared to zoster live vaccine (Zostavax) 

Immunocompromised older adults compared to placebo or unvaccinated

 

Note: These GRADE documents should be read as a supplement to Australian Immunisation Handbook recommendations.

View the zoster disease chapter in the Handbook here
View the ATAGI statement on the clinical use of zoster vaccine in older adults in Australia here

Last updated February 2024